Skip navigation.

HOME > Publications > Proceedings of the Japan Academy, Ser. B, Physical and Biological Sciences

Proceedings of the Japan Academy, Ser. B, Physical and Biological Sciences


Project Euclid


PubMed Logo

The Proceedings of the Japan Academy, Series B was founded in 1912 as the Proceedings of the Imperial Academy by the then Imperial Academy of Japan (now the Japan Academy). The Journal was split to the Proceedings of the Japan Academy, Series A and Series B in 1977. PJA Series B publishes reviews and original articles in broad fields of natural sciences, such as chemistry, physics, astronomy, earth sciences, biology, engineering, agricultural sciences and medical sciences. All manuscripts are evaluated at least by two reviewers. Ten issues are published per year. The entire content is now freely available online through J-STAGE.

Vol. 93 No. 3 (2017)

Finite-block-length analysis in classical and quantum information theory
Masahito HAYASHI
Proc. Jpn. Acad., Ser. B, Vol. 93, 99-124 (2017) [Abstract and Full Text]
Development of chemical and chemo-enzymatic glycosylations
Shin-ichiro SHODA
Proc. Jpn. Acad., Ser. B, Vol. 93, 125-145 (2017) [Abstract and Full Text]
Getting to the heart of the matter in cancer: Novel approaches to targeting cancer stem cells
Hugh COLVIN and Masaki MORI
Proc. Jpn. Acad., Ser. B, Vol. 93, 146-154 (2017) [Abstract and Full Text]
Cover Illustration
Targeting Stem Cells in Cancer
  Many cancers recur at a later date despite an initial favorable response to radio- or chemotherapy. In some cases, recurrence can occur even after 10 years following the treatment. Cancer stem cells could explain this phenomenon. While cancer stem cells may make up only a small fraction of the cancer tissue, these cells are able to self-renew and give rise to the different cell types that compose the cancer tissue. Compared to the non-cancer stem cells, cancer stem cells are more resistant to therapeutic interventions, leading to their survival after treatment and to give rise to recurrence at a later date (A). Here in the front cover photographs, Dr. Mori has labelled the cancer stem cells fluorescent green, through transfection of the cells with a fusion protein made up of a green fluorescent protein and a C-terminal degron of the ornithine decarboxylase that is normally destroyed by proteasomes. Because cancer stem cells have low proteasome activity, they retain the fusion protein. However, the fusion protein is degraded in the non-cancer stem cells. When undergoing cell division, cancer stem cells can produce a fluorescent cancer stem cell and a non-fluorescent daughter cell (B). The daughter cell then continues to divide multiple times (C and D), to give rise to the bulk of the cancer cell population (E). However, the cancer stem cell is capable of renewing the entire cell population of the cancer. Therefore, the targeting of cancer stem cells for treatment holds promise for the complete and long-lasting eradication of cancer. In pages 146-154 of this issue, Dr. Mori explains the strategies he has developed to target cancer stem cells.
Hideyuki Saya
Keio University School of Medicine

↑Go to TOP